Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000824792 | SCV000065515 | pathogenic | Rare genetic deafness | 2012-11-05 | criteria provided, single submitter | clinical testing | The Thr967fs variant in USH2A has been reported in at least three individuals wi th Usher syndrome, two of whom were homozygous, and was found to segregate with disease in one affected family member (Eudy 1998, Weston 2000, Seyedahmadi 2004, Jaijo 2010). This frameshift variant is predicted to alter the protein?s amino acid sequence beginning at position 967 and lead to a premature termination cod on 44 amino acids downstream. This alteration is then predicted to lead to a tru ncated or absent protein. In summary, this variant meets our criteria to be clas sified as pathogenic (http://pcpgm.partners.org/LMM). |
Counsyl | RCV000671576 | SCV000796564 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-12-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001851582 | SCV002228487 | pathogenic | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr967Leufs*44) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Usher syndrome type IIa (PMID: 9624053). This variant is also known as 2913delG. ClinVar contains an entry for this variant (Variation ID: 2352). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003450613 | SCV004182389 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000002446 | SCV004182390 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003450613 | SCV004206284 | pathogenic | Retinitis pigmentosa 39 | 2023-03-20 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000002446 | SCV000022604 | pathogenic | Usher syndrome type 2A | 2000-04-01 | no assertion criteria provided | literature only | |
Natera, |
RCV000002446 | SCV002093942 | pathogenic | Usher syndrome type 2A | 2020-11-20 | no assertion criteria provided | clinical testing |